Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:

BioCentury Newsmakers in the Biotech Industry

Thursday, September 4, 2008, 10:00 AM Eastern time

Millennium Broadway Hotel, New York

UBS Global Life Sciences Conference

Tuesday, September 23, 2008, 9:30 AM Eastern time

Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at

SOURCE Orexigen Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
2. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Pixel Bridge Works With Anika Therapeutics to Launch New Website
8. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
9. Arno Therapeutics Announces Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - ... "Company") announced today that the remaining 11,000 post-share ... Share Purchase Warrants (the "Series B Warrants") subject ... were exercised on November 23, 2015, which will ... Shares.  After giving effect to the issuance of ...
Breaking Biology Technology:
(Date:11/20/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... recently interviewed on The RedChip Money Report ... on Bloomberg Europe , Bloomberg Asia, Bloomberg Australia, ... NXTD ) ("NXT-ID" or the "Company"), a biometric authentication ...
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... 2015 Paris , ... --> Paris , qui s,est tenu ... le leader de l,innovation biométrique, a inventé le premier ... empreintes sur la même surface de balayage. Jusqu,ici, deux ... pour les empreintes digitales. Désormais, un seul scanner est ...
Breaking Biology News(10 mins):